参考文献/References:
[1] Djalalinia S, Qorbani M, Peykari N,et al. Health impacts of obesity[J]. Pak J Med Sci,2015,31(1):239-242. DOI: 10.12669/pjms.311.7033.
[2] Finkelstein EA, Khavjou OA, Thompson H,et al. Obesity and severe obesity forecasts through 2030[J].Am J Prev Med,2012,42(6):563-570. DOI: 10.1016/j.amepre.2011.10.026.
[3] Jones BJ, Bloom SR. The new era of drug therapy for obesity: the evidence and the expectations[J].Drugs,2015,75(9):935-945. DOI: 10.1007/s40265-015-0410-1.
[4] Kim JE, Lee MH, Nam DH,et al. Celastrol, an NF-κB inhibitor, improves insulin resistance and attenuates renal injury in db/db mice[J].PLoS One,2013,8(4):e62068. DOI: 10.1371/journal.pone.0062068.
[5] Liu J, Lee J, Salazar Hernandez MA,et al. Treatment of obesity with celastrol[J].Cell,2015,161(5):999-1011. DOI: 10.1016/j.cell.2015.05.011.
[6] Ma X, Xu L, Alberobello AT,et al. Celastrol protects against obesity and metabolic dysfunction through activation of a HSF1-PGC1α transcriptional axis[J].Cell Metab,2015,22(4):695-708. DOI: 10.1016/j.cmet.2015.08.005.
[7] Wang C, Shi C, Yang X,et al. Celastrol suppresses obesity process via increasing antioxidant capacity and improving lipid metabolism[J].Eur J Pharmacol,2014,744:52-58. DOI: 10.1016/j.ejphar.2014.09.043.
[8] Kannaiyan R, Shanmugam MK, Sethi G. Molecular targets of celastrol derived from Thunder of God Vine: potential role in the treatment of inflammatory disorders and cancer[J].Cancer Lett,2011,303(1):9-20. DOI: 10.1016/j.canlet.2010.10.025.
[9] Ramírez S, Claret M. Hypothalamic ER stress: a bridge between leptin resistance and obesity[J].FEBS Lett,2015,589(14):1678-1687. DOI: 10.1016/j.febslet.2015.04.025.
[10] Liu C, Lin JD. PGC-1 coactivators in the control of energy metabolism[J].Acta Biochim Biophys Sin(Shanghai),2011,43(4):248-257. DOI: 10.1093/abbs/gmr007.
[11] Jia G, Aroor AR, DeMarco VG,et al. Vascular stiffness in insulin resistance and obesity[J].Front Physiol,2015,6:231. DOI: 10.3389/fphys.2015.00231.
[12] Abu Bakar MH, Cheng KK, Sarmidi MR,et al. Celastrol protects against antimycin a-induced insulin resistance in human skeletal muscle cells[J].Molecules,2015,20(5):8242-8269.DOI: 10.3390/molecules20058242.
[13] Bakar MH, Sarmidi MR, Kai CK,et al. Amelioration of mitochondrial dysfunction-induced insulin resistance in differentiated 3T3-L1 adipocytes via inhibition of NF-κB pathways[J].Int J Mol Sci,2014,15(12):22227-22257. DOI: 10.3390/ijms151222227.
[14] Baker RG, Hayden MS, Ghosh S. NF-kappaB, inflammation, and metabolic disease[J]. Cell Metab, 2011,13(1):11-22.DOI:10.1016/j.cmet.2010.12.008.
[15] Crescenzo R, Bianco F, Mazzoli A, et al. Mitochondrial efficiency and insulin resistance[J].Front Physiol, 2014,5:512.DOI:10.3389/fphys.2014.00512.
相似文献/References:
[1]常海瑶,刘晶,吴文昊,等.血管生成素样蛋白6、瘦素与糖尿病肾病的关系[J].国际内分泌代谢杂志,2020,40(05):289.[doi:10.3760/cma.j.cn121383-20200208-02009]
Chang Haiyao,Liu Jing,Wu Wenhao,et al.Relationship between angiogenin-like protein 6, leptin and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2020,40(01):289.[doi:10.3760/cma.j.cn121383-20200208-02009]
[2]齐晨蕊,杨乐,马彦,等.绝经后2型糖尿病患者瘦素、骨代谢标志物与OP的关系[J].国际内分泌代谢杂志,2024,44(03):177.[doi:10.3760/cma.j.cn121383-20231213-12038]
Qi Chenrui,Yang Le,Ma Yan,et al.Relationship between leptin, bone metabolic markers and OP in postmenopausal patients with type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2024,44(01):177.[doi:10.3760/cma.j.cn121383-20231213-12038]
[3]王姝洁,张翼飞,张志国.雷公藤红素在治疗代谢综合征中的作用及相关机制[J].国际内分泌代谢杂志,2017,37(04):258.
Wang Shujie,Zhang Yifei,Zhang Zhiguo..Effects and related mechanisms of celastrol in the treatment of metabolic syndrome[J].International Journal of Endocrinology and Metabolism,2017,37(01):258.